

Claim Listing

Claims 1-28 (canceled).

Claim 29. (original) A method of evaluating the propensity of a patient to develop schizophrenia comprising:

determining a nucleotide from a nucleic acid obtained from said patient which corresponds to the nucleotide occupying one or more Seq-40 polymorphic sites at positions

- 1) 601 and 1038,
- (2) 194 and 1038,
- (3) 601 and 2106,
- (4) 194 and 2106,
- (5) 194 and 601,
- (6) 1038 and 2106,
- (7) 601, 1038 and 2106,
- (8) 601, 1038 and 2185,
- (9) 194, 1038 and 2106,
- (10) 194, 601 and 1038,
- (11) 194, 1038 and 2185,
- (12) 601, 1038 and 2359,
- (13) 194, 601 and 2106,
- (14) 194, 601 and 1038,
- (15) 601, 2106 and 2359,
- (16) 601, 2106 and 2185,
- (17) 601, 1038 and 2106,
- (18) 601, 1038 and 2359,
- (19) 194, 601 and 2106,
- (20) 601, 1038, 2106 and 2185,
- (21) 194, 601, 1038 and 2106,
- (22) 194, 1038, 2106 and 2185,
- (23) 194, 601, 1038 and 2185,
- (24) 601, 1038, 2185 and 2359,
- (25) 601, 1038, 2106 and 2359,

(26) 194, 1038, 2185 and 2359 and

(27) 194, 601, 1038 and 2359

of SEQ ID NO: 1 on a single chromosome, and evaluating whether the patient has a propensity to develop schizophrenia.

Claim 30. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C.

Claim 31. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C.

Claim 32. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 33. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 34. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is a G and if

Attorney Docket No. 01313.US1 renumbered as PC 27689A
the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof
is a G.

Claim 35. (original) The method of claim 29, wherein the evaluation step comprises
determining that the patient has less of a propensity to develop schizophrenia if the
identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a
G and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a
fragment thereof is an A.

Claim 36. (original) The method of claim 29, wherein the evaluation step comprises
determining that the patient has less of a propensity to develop schizophrenia if the
identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a
G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment
thereof is a C and if the identity of the nucleotide at position 2106 of SEQ ID NO:1
or a fragment thereof is a G.

Claim 37. (original) The method of claim 29, wherein the evaluation step comprises
determining that the patient has a propensity to develop schizophrenia if the identity
of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the
identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is
a C and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a
fragment thereof is a G.

Claim 38. (original) The method of claim 29, wherein the evaluation step comprises
determining that the patient has less of a propensity to develop schizophrenia if the
identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an
A, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment
thereof is a C and if the identity of the nucleotide at position 2106 of SEQ ID NO:1
or a fragment thereof is a G.

Claim 39. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is a A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C

Claim 40. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C or G and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G or A.

Claim 41. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 42. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is an A.

Claim 43. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a

G and if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C.

Claim 44. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 45. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 46. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is an A and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is an A.

Claim 47. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a T.

Claim 48. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has less of a propensity to develop schizophrenia if the

Attorney Docket No. 01313.US1 renumbered as PC 27689A
identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 49. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 50. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has less of a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 51. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment thereof is a G and if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment thereof is a G.

Claim 52. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof

Patent Application

Attorney Docket No. 01313.US1 renumbered as PC 27689A
is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a
fragment thereof is a C and if the identity of the nucleotide at position 2185 of SEQ
ID NO:1 or a fragment thereof is a G.

Claim 53. (original) The method of claim 29, wherein the evaluation step comprises
determining that the patient has a propensity to develop schizophrenia if the identity
of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the
identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is
a C, if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a fragment
thereof is a G and if the identity of the nucleotide at position 2359 of SEQ ID NO:1
or a fragment thereof is a T.

Claim 54. (original) The method of claim 29, wherein the evaluation step comprises
determining that the patient has a propensity to develop schizophrenia if the identity
of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the
identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is
a C, if the identity of the nucleotide at position 2106 of SEQ ID NO:1 or a fragment
thereof is a G and if the identity of the nucleotide at position 2359 of SEQ ID NO:1
or a fragment thereof is a T or G.

Claim 55. (original) The method of claim 29, wherein the evaluation step comprises
determining that the patient has a propensity to develop schizophrenia if the identity
of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if
the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof
is a C, if the identity of the nucleotide at position 2185 of SEQ ID NO:1 or a
fragment thereof is a G and if the identity of the nucleotide at position 2359 of SEQ
ID NO:1 or a fragment thereof is a T.

Patent Application
Attorney Docket No. 01313.US1 renumbered as PC 27689A

Claim 56. (original) The method of claim 29, wherein the evaluation step comprises determining that the patient has a propensity to develop schizophrenia if the identity of the nucleotide at position 194 of SEQ ID NO:1 or a fragment thereof is an A, if the identity of the nucleotide at position 601 of SEQ ID NO:1 or a fragment thereof is a G, if the identity of the nucleotide at position 1038 of SEQ ID NO:1 or a fragment thereof is a C and if the identity of the nucleotide at position 2359 of SEQ ID NO:1 or a fragment thereof is a G.